Chantal Csajka

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


225 publications

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | ...
2023
Apixaban and rivaroxaban's physiologically-based pharmacokinetic model validation in hospitalized patients: A first step for larger use of a priori modeling approach at bed side.
Terrier J., Gaspar F., Gosselin P., Raboud O., Lenoir C., Rollason V., Csajka C., Samer C., Fontana P., Daali Y. et al., 2023/12. CPT, 12 (12) pp. 1872-1883. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DB8C3D56D13E]
 
Modulateurs de la protéine CFTR pour traiter la mucoviscidose
Di Paolo E.R., Mitropoulou G., Csajka C, 2023/10/06. La Gazette médicale, 12 (06) pp. 20-22.
[serval:BIB_B4DC6837999E]
Population pharmacokinetics of apixaban in a real-life hospitalized population from the OptimAT study.
Gaspar F., Terrier J., Favre S., Gosselin P., Fontana P., Daali Y., Lenoir C., Samer C.F., Rollason V., Reny J.L. et al., 2023/10. CPT, 12 (10) pp. 1541-1552. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2BD727D8058F]
Predicting delirium in older non-intensive care unit inpatients: development and validation of the DELIrium risK Tool (DELIKT).
Schulthess-Lisibach A.E., Gallucci G., Benelli V., Kälin R., Schulthess S., Cattaneo M., Beeler P.E., Csajka C., Lutters M., 2023/10. International journal of clinical pharmacy, 45 (5) pp. 1118-1127. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4C90B4517DE7]
Modeling tumor size dynamics based on real-world electronic health records and image data in advanced melanoma patients receiving immunotherapy.
Courlet P., Abler D., Guidi M., Girard P., Amato F., Vietti Violi N., Dietz M., Guignard N., Wicky A., Latifyan S. et al., 2023/08. CPT, 12 (8) pp. 1170-1181. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A319336A78BD]
 
Modulatoren des CFTR-Proteins zur Behandlung der Mukoviszidose
Di Paolo E.R., Mitropoulou G., Csajka C., 2023/07/01. Der informierte @rtz, 13 (07) pp. 29-31.
[serval:BIB_E49900AC8E64]
Semiautomated Pipeline to Quantify Tumor Evolution From Real-World Positron Emission Tomography/Computed Tomography Imaging.
Abler D., Courlet P., Dietz M., Gatta R., Girard P., Munafo A., Wicky A., Jreige M., Guidi M., Latifyan S. et al., 2023/05. JCO clinical cancer informatics, 7 pp. e2200126. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_D61806C1E839]
Dementia prevention in memory clinics: recommendations from the European task force for brain health services.
Frisoni G.B., Altomare D., Ribaldi F., Villain N., Brayne C., Mukadam N., Abramowicz M., Barkhof F., Berthier M., Bieler-Aeschlimann M. et al., 2023/03. The Lancet regional health. Europe, 26 p. 100576. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_46E732772F5F]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
From personalized to precision medicine in oncology: A model-based dosing approach to optimize achievement of imatinib target exposure.
Goutelle S., Guidi M., Gotta V., Csajka C., Buclin T., Widmer N., 2023. Pharmaceutics, 15 (4) p. 1081. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_829AAAA406A8]
Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project.
Monfort A., Cardoso E., Eap C.B., Fischer Fumeaux C.J., Graz M.B., Morisod Harari M., Weisskopf E., Gandia P., Allegaert K., Nordeng H. et al., 2023. Frontiers in psychiatry, 14 p. 1167870. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EE8A9936EA15]
2022
Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.
Mitropoulou G., Koutsokera A., Csajka C., Blanchon S., Sauty A., Brunet J.F., von Garnier C., Resch G., Guery B., 2022/12/31. European respiratory review, 31 (166) p. 220121. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E890AE6D6C1D]
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Schmulenson E., Bovet C., Theurillat R., Decosterd L.A., Largiadèr C.R., Prost J.C., Csajka C., Bärtschi D., Guckenberger M., von Moos R. et al., 2022/12. British journal of clinical pharmacology, 88 (12) pp. 5336-5347. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FD41EC93A336]
 
Phagothérapie pour traiter les infections respiratoires [Phage therapy for respiratory infections]
Mitropoulou G., Gijs P.J., Koutsokera A., Sauty A., Blanchon S., Csajka C., Brunet J.F., Resch G., Guery B., Von Garnier C., 2022/11/16. Revue medicale suisse, 18 (804) pp. 2150-2156. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CCFF1CBAD0AE]
 
Automatic Detection of Adverse Drug Events in Geriatric Care: Study Proposal.
Gaspar F., Lutters M., Beeler P.E., Lang P.O., Burnand B., Rinaldi F., Lovis C., Csajka C., Le Pogam M.A., SwissMADE study, 2022/11/15. JMIR research protocols, 11 (11) pp. e40456. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A5F29ECD8BC]
Evaluation of the association of anticholinergic burden and delirium in older hospitalised patients - A cohort study comparing 19 anticholinergic burden scales.
Lisibach A., Gallucci G., Benelli V., Kälin R., Schulthess S., Beeler P.E., Csajka C., Lutters M., 2022/11. British journal of clinical pharmacology, 88 (11) pp. 4915-4927. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4DDB0E74DD7C]
Impact of Pharmaceutical Interventions with STOPP/START and PIM-Check in Older Hospitalized Patients: A Randomized Controlled Trial.
Farhat A., Al-Hajje A., Lang P.O., Csajka C., 2022/11. Drugs & aging, 39 (11) pp. 899-910. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_570B94333C1E]
Implementation and Cross-Validation of a Pharmacokinetic Model for Precision Dosing of Busulfan in Hematopoietic Stem Cell Transplanted Children.
Goutelle S., Thoma Y., Buffet R., Philippe M., Buclin T., Guidi M., Csajka C., 2022/10/01. Pharmaceutics, 14 (10) p. 2107. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1F77B194CA9D]
 
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T., Puszkiel A., Cardoso E., Balakirouchenane D., Narjoz C., Arrondeau J., Fallet V., Khoudour N., Guidi M., Vidal M. et al., 2022/09/01. Pharmaceutics, 14 (9) p. 1844. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_72EF703BC03A]
Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation.
Terrier J., Gaspar F., Guidi M., Fontana P., Daali Y., Csajka C., Reny J.L., 2022/08. Clinical pharmacology and therapeutics, 112 (2) pp. 353-363. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2F23BCB64F8E]
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7FBC59504B2]
 
Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland.
Bandiera C., Skrabal Ross X., Cardoso E., Wagner D., Csajka C., Olver I., Patterson P., Suppiah V., Gunn K.M., Schneider M., 2022/05. Supportive care in cancer, 30 (5) pp. 3655-3659. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F808DD17629]
Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation.
Dao K., Fuchs A., André P., Giannoni E., Decosterd L.A., Marchetti O., Asner S.A., Pfister M., Widmer N., Buclin T. et al., 2022/02/02. The Journal of antimicrobial chemotherapy, 77 (2) pp. 457-465. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6EBEF14704F8]
High anticholinergic burden at admission associated with in-hospital mortality in older patients: A comparison of 19 different anticholinergic burden scales.
Lisibach A., Gallucci G., Beeler P.E., Csajka C., Lutters M., 2022/02. Basic & clinical pharmacology & toxicology, 130 (2) pp. 288-300. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5C4A662F2F17]
 
Parametric and Nonparametric Methods in Population Pharmacokinetics: Experts' Discussion on Use, Strengths, and Limitations.
Goutelle S., Woillard J.B., Buclin T., Bourguignon L., Yamada W., Csajka C., Neely M., Guidi M., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 158-170. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E083EEFD4CCE]
 
Parametric Approaches in Population Pharmacokinetics.
Guidi M., Csajka C., Buclin T., 2022/02. Journal of clinical pharmacology, 62 (2) pp. 125-141. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4AEA287B02AD]
Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis.
Bandiera C., Pasquier J., Locatelli I., Niquille A., Wuerzner G., Dotta-Celio J., Hachfeld A., Wandeler G., Wagner A.D., Csajka C. et al., 2022. Patient preference and adherence, 16 pp. 2313-2320. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_813F43A545D0]
2021
Ability to detect potentially inappropriate prescribing in older patients: comparative analysis between PIM-Check and STOPP/STARTv2.
Farhat A., Panchaud A., Al-Hajje A., Lang P.O., Csajka C., 2021/11. European journal of clinical pharmacology, 77 (11) pp. 1747-1756. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F1DB8BDAA204]
Protocols for cognitive enhancement. A user manual for Brain Health Services-part 5 of 6.
Brioschi Guevara A., Bieler M., Altomare D., Berthier M., Csajka C., Dautricourt S., Démonet J.F., Dodich A., Frisoni G.B., Miniussi C. et al., 2021/10/11. Alzheimer's research & therapy, 13 (1) p. 172. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F39EC11590C2]
 
Clinical and economic impacts of explicit tools detecting prescribing errors: A systematic review.
Farhat A., Al-Hajje A., Csajka C., Panchaud A., 2021/08. Journal of clinical pharmacy and therapeutics, 46 (4) pp. 877-886. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E9B3E8C32619]
Cross-cultural adaptation and psychometric validation of the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire in French.
Roux B., Sirois C., Niquille A., Spinewine A., Ouellet N., Pétein C., Sibille F.X., Csajka C., Reeve E., Villeneuve C. et al., 2021/08. Research in social & administrative pharmacy, 17 (8) pp. 1453-1462. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0F9DB519D21F]
 
Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians.
Terrier J., Gaspar F., Fontana P., Youssef D., Reny J.L., Csajka C., Samer C.F., 2021/08. The American journal of medicine, 134 (8) pp. 939-942. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4ADAFEEDAF54]
 
Once-daily 1 g ceftriaxone optimizes exposure in patients with septic shock and hypoalbuminemia receiving continuous veno-venous hemodiafiltration.
Ulldemolins M., Bastida C., Llauradó-Serra M., Csajka C., Rodríguez A., Badia J.R., Martín-Loeches I., Soy D., 2021/08. European journal of clinical pharmacology, 77 (8) pp. 1169-1180. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F72758826E29]
Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.
Courlet P., Guidi M., Alves Saldanha S., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A., Csajka C., 2021/07. European journal of clinical pharmacology, 77 (7) pp. 979-987. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_DCBBE5FFBE88]
Pharmacokinetic/Pharmacodynamic Modelling to Describe the Cholesterol Lowering Effect of Rosuvastatin in People Living with HIV.
Courlet P., Guidi M., Alves Saldanha S., Stader F., Traytel A., Cavassini M., Stoeckle M., Buclin T., Marzolini C., Decosterd L.A. et al., 2021/03. Clinical pharmacokinetics, 60 (3) pp. 379-390. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CF76FDD25628]
Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review.
Lisibach A., Benelli V., Ceppi M.G., Waldner-Knogler K., Csajka C., Lutters M., 2021/02. European journal of clinical pharmacology, 77 (2) pp. 147-162. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BFD95CBADD31]
 
Automated Detection of Adverse Drug Events from Older Patients' Electronic Medical Records Using Text Mining
Colic Nicola, Beeler Patrick, Csajka Chantal, Foufi Vasiliki, Gaspar Frederic, Pogam Marie-Annick Le, Lisibach Angela, Lovis Christian, Lutters Monika, Rinaldi Fabio, 2021. pp. 203-211 dans Pattern Recognition. ICPR International Workshops and Challenges, Springer International Publishing.
[DOI][serval:BIB_0EBA03943A2C]
Impact of Pharmaceutical Interventions in Hospitalized Patients: A Comparative Study Between Clinical Pharmacists and an Explicit Criteria-Based Tool.
Farhat A., Abou-Karroum R., Panchaud A., Csajka C., Al-Hajje A., 2021. Current therapeutic research, clinical and experimental, 95 p. 100650. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_468B1ED3F169]
 
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR research protocols, 10 (6) pp. e30090. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7657CD7990C9]
2020
Validation and clinical application of a multiplex high performance liquid chromatography - tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections.
Decosterd L.A., Mercier T., Ternon B., Cruchon S., Guignard N., Lahrichi S., Pesse B., Rochat B., Burger R., Lamoth F. et al., 2020/11/10. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1157 p. 122160. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2ABB9B287690]
Enquête « RTO-COVID-19 » : nos soins, nos actions, leurs effets
Graz B., Houriet J., Willcox M., Csajka C., 2020/08/26. Revue medicale suisse, 16 (703) pp. 1522-1523. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_08A6DD2A517F]
 
A population pharmacokinetic model for escitalopram and its major metabolite in depressive patients during the perinatal period: Prediction of infant drug exposure through breast milk.
Weisskopf E., Guidi M., Fischer C.J., Bickle Graz M., Beaufils E., Nguyen K.A., Morisod Harari M., Rouiller S., Rothenburger S., Gaucherand P. et al., 2020/08. British journal of clinical pharmacology, 86 (8) pp. 1642-1653. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6EA0D4637119]
Influence of Drug-Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV.
Courlet P., Decosterd L.A., Alves Saldanha S., Cavassini M., Stader F., Stoeckle M., Buclin T., Marzolini C., Csajka C., Guidi M. et al., 2020/08. Clinical pharmacokinetics, 59 (8) pp. 1037-1048. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B56252981556]
 
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Cardoso E., Guidi M., Khoudour N., Boudou-Rouquette P., Fabre E., Tlemsani C., Arrondeau J., Goldwasser F., Vidal M., Schneider M.P. et al., 2020/07. Clinical therapeutics, 42 (7) pp. 1302-1316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C945C7298567]
Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P., Alves Saldanha S., Cavassini M., Marzolini C., Choong E., Csajka C., Günthard H.F., André P., Buclin T., Desfontaine V. et al., 2020/06. Journal of mass spectrometry, 55 (6) pp. e4506. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1D794571C1B2]
Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma.
Balakirouchenane D., Guégan S., Csajka C., Jouinot A., Heidelberger V., Puszkiel A., Zehou O., Khoudour N., Courlet P., Kramkimel N. et al., 2020/04/09. Cancers, 12 (4). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E1BBC7ED0901]
Optimisation of vancomycin exposure in neonates based on the best level of evidence.
Dao K., Guidi M., André P., Giannoni E., Basterrechea S., Zhao W., Fuchs A., Pfister M., Buclin T., Csajka C., 2020/04. Pharmacological research, 154 p. 104278. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E0DB9448258C]
Amisulpride: Real-World Evidence of Dose Adaptation and Effect on Prolactin Concentrations and Body Weight Gain by Pharmacokinetic/Pharmacodynamic Analyses.
Glatard A., Guidi M., Delacrétaz A., Dubath C., Grosu C., Laaboub N., von Gunten A., Conus P., Csajka C., Eap C.B., 2020/03. Clinical pharmacokinetics, 59 (3) pp. 371-382. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_750BA5D2C6D5]
 
Contribution of Genetic Background and Data Collection on Adverse Events of Anti-human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate.
Dietrich L.G., Barceló C., Thorball C.W., Ryom L., Burkhalter F., Hasse B., Furrer H., Weisser M., Steffen A., Bernasconi E. et al., 2020/02/14. Clinical infectious diseases, 70 (5) pp. 890-897. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CEFAD592E5CD]
Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy.
Barceló C., Guidi M., Thorball C.W., Hammer C., Chaouch A., Scherrer A.U., Hasse B., Cavassini M., Furrer H., Calmy A. et al., 2020/01. Open forum infectious diseases, 7 (1) pp. ofz464. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_7951F9D906D0]
The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib
Buclin T., Thoma Y., Widmer N., André P., Guidi M., Csajka C., Decosterd L..A., 2020. Frontiers in Pharmacology, 11 p. 177. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_9A25C1CC37D8]
 
Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review.
Cardoso E., Guidi M., Blanchet B., Schneider M.P., Decosterd L.A., Buclin T., Csajka C., Widmer N., 2020. Therapeutic Drug Monitoring, 42 (1) pp. 33-44. Peer-reviewed.
[DOI][Pmid][serval:BIB_2BF80A005C57]
2019
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7C76EA90383]
Polypharmacy, Drug-Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV.
Courlet P., Livio F., Guidi M., Cavassini M., Battegay M., Stoeckle M., Buclin T., Alves Saldanha S., Csajka C., Marzolini C. et al., 2019/12. Open forum infectious diseases, 6 (12) pp. ofz531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_747A12E6A2E6]
 
Towards Personalized Antithrombotic Treatments: Focus on P2Y<sub>12</sub> Inhibitors and Direct Oral Anticoagulants.
Terrier J., Daali Y., Fontana P., Csajka C., Reny J.L., 2019/12. Clinical pharmacokinetics, 58 (12) pp. 1517-1532. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AC8A16216FE8]
 
Gestion du traitement de l’asthme chez une femme enceinte
Levray Andréa, Berger Jérôme, Guignard Bertrand, Beney Johnny, Csajka Chantal, Panchaud Alice, 2019/10. pharmaJournal.
[serval:BIB_01CC04D18510]
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence - an update.
Fischer Fumeaux C.J., Morisod Harari M., Weisskopf E., Eap C.B., Epiney M., Vial Y., Csajka C., Bickle Graz M., Panchaud A., 2019/10. Expert opinion on drug safety, 18 (10) pp. 949-963. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AACEB7EFC408]
 
Therapiemanagement von Asthma bei einer schwangeren Frau
Levray Andréa, Berger Jérôme, Guignard Bertrand, Beney Johnny, Csajka Chantal, Panchaud Alice, 2019/10. pharmaJournal.
[serval:BIB_45CF28833B1E]
 
Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
Courlet P., Guidi M., Glatard A., Alves Saldanha S., Cavassini M., Buclin T., Marzolini C., Eap C.B., Decosterd L.A., Csajka C. et al., 2019/09. British journal of clinical pharmacology, 85 (9) pp. 2022-2032. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F5C6318349C9]
 
Population pharmacokinetics of dolutegravir: influence of drug-drug interactions in a real-life setting.
Barcelo C., Aouri M., Courlet P., Guidi M., Braun D.L., Günthard H.F., Piso R.J., Cavassini M., Buclin T., Decosterd L.A. et al., 2019/09/01. The Journal of antimicrobial chemotherapy, 74 (9) pp. 2690-2697. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_525CE7DE74FD]
 
UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV.
Courlet P., Spaggiari D., Desfontaine V., Cavassini M., Alves Saldanha S., Buclin T., Marzolini C., Csajka C., Decosterd L.A., 2019/09/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1125 p. 121733. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_00B59FADA800]
 
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Courlet P., Decosterd L.A., Brown J.A., Alves Saldanha S., Marzolini C., Cavassini M., Stoeckle M., Csajka C., Labhardt N.D., Calmy A. et al., 2019/08/01. The Journal of antimicrobial chemotherapy, 74 (8) pp. 2468-2470. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5082024839D9]
Influence of body weight and UGT2B7 polymorphism on varenicline exposure in a cohort of smokers from the general population.
Glatard A., Guidi M., Dobrinas M., Cornuz J., Csajka C., Eap C.B., 2019/07. European journal of clinical pharmacology, 75 (7) pp. 939-949. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1B9CBBB244BC]
Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.
Guidi M., Mercier T., Aouri M., Decosterd L.A., Csajka C., Ogutu B., Carn G., Kiechel J.R., 2019/04/18. Malaria journal, 18 (1) p. 139. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BBD62F6B6F27]
Complementary medicine use during cancer treatment and potential herb-drug interactions from a cross-sectional study in an academic centre.
Jermini M., Dubois J., Rodondi P.Y., Zaman K., Buclin T., Csajka C., Orcurto A., Rothuizen L.E., 2019/03/25. Scientific reports, 9 (1) p. 5078. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EB0D132F2B63]
 
Reply to L. Pala et al.
Wagner A.D., Özdemir B., Csajka C., 2019/02/10. Journal of clinical oncology, 37 (5) pp. 439-440. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3B355EA54937]
Adherence to intermittent preventive treatment for malaria in Papua New Guinean infants: A pharmacological study alongside the randomized controlled trial.
Sottas O., Guidi M., Thieffry B., Schneider M., Décosterd L., Mueller I., Genton B., Csajka C., Senn N., 2019. PloS one, 14 (2) pp. e0210789. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A2EC9261874C]
 
Precision dosing of imatinib: A model-based approach to optimize achievement of target exposure
Goutelle S., Widmer N., Buclin T., Csajka C., 2019., 23e Congrès de la Société Française de Pharmacologie et de Thérapeutique p. 35 dans Fundamental & Clinical Pharmacology. Peer-reviewed.
[DOI][WoS][serval:BIB_CB35B290E537]
2018
 
Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
Burger R., Guidi M., Calpini V., Lamoth F., Decosterd L., Robatel C., Buclin T., Csajka C., Marchetti O., 2018/12/01. The Journal of antimicrobial chemotherapy, 73 (12) pp. 3413-3422. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C826664F7442]
 
Quelle alternative aux benzodiazépines, Z-pills et autres hypnotiques pour les personnes âgées ?: Mélatonine, valériane ou clométhiazole [Which alternative to benzodiazepines, Z-pills and other hypnotics for aged people ? Melatonin, valerian, or clomethiazole]
Dumur J., Csajka C., Pavec O., Messaoudi S., Cretignier T., Gaspar F., Lang P.O., 2018/11/07. Revue medicale suisse, 14 (626) pp. 2018-2023. Peer-reviewed.
[Pmid][serval:BIB_CAD3AAF98D1E]
 
Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology.
Özdemir B.C., Csajka C., Dotto G.P., Wagner A.D., 2018/09/10. Journal of clinical oncology, 36 (26) pp. 2680-2683. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1AE7BE4F2A08]
 
Population Pharmacokinetic Study of Amoxicillin-Treated Burn Patients Hospitalized at a Swiss Tertiary-Care Center.
Fournier A., Goutelle S., Que Y.A., Eggimann P., Pantet O., Sadeghipour F., Voirol P., Csajka C., 2018/09. Antimicrobial agents and chemotherapy, 62 (9) pp. e00505-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_936107FB37E5]
 
Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.
Cardoso E., Mercier T., Wagner A.D., Homicsko K., Michielin O., Ellefsen-Lavoie K., Cagnon L., Diezi M., Buclin T., Widmer N. et al., 2018/04/15. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1083 pp. 124-136. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E8B0234B5672]
 
Quantitative Analysis of Gentamicin Exposure in Neonates and Infants Calls into Question Its Current Dosing Recommendations.
van Donge T., Pfister M., Bielicki J., Csajka C., Rodieux F., van den Anker J., Fuchs A., 2018/04. Antimicrobial agents and chemotherapy, 62 (4) pp. e02004-17 . Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2DD56A53FB50]
 
Pregnancy outcomes in women on metformin for diabetes or other indications among those seeking teratology information services.
Panchaud A., Rousson V., Vial T., Bernard N., Baud D., Amar E., De Santis M., Pistelli A., Dautriche A., Beau-Salinas F. et al., 2018/03. British journal of clinical pharmacology, 84 (3) pp. 568-578. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B81A0F10409F]
 
Exploiting Pharmacokinetic Models of Tamoxifen and Endoxifen to Identify Factors Causing Subtherapeutic Concentrations in Breast Cancer Patients.
Klopp-Schulze L., Joerger M., Wicha S.G., Ter Heine R., Csajka C., Parra-Guillen Z.P., Kloft C., 2018/02. Clinical pharmacokinetics, 57 (2) pp. 229-242. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A8448D11AA3D]
 
Détection des prescriptions inappropriées, les critères STOPP/START [Detection of inappropriate prescribing, STOPP/START criteria]
Lang Pierre Olivier, Bourgue Chloé, Csajka Chantal, 2018/01. Actualités Pharmaceutiques, 57 (572) pp. 26-32. Peer-reviewed.
[DOI][WoS][serval:BIB_CA83CDBD7EF7]
 
Effect of adherence on pharmacokinetic/pharmacodynamic relationships of oral targeted anticancer drugs.
Cardoso E., Csajka C., Schneider M.P., Widmer N., 2018/01. Clinical Pharmacokinetics, 57 (1) pp. 1-6. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0672F55D1702]
2017
 
Détecter et évaluer l’impact desmédicaments anticholinergiques [Detecting and assessing the impactof anticholinergic medications]
Csajka C., Brémond C., Lang P.O., 2017/11/08. Revue medicale suisse, 13 (582) pp. 1931-1937. Peer-reviewed.
[Pmid][serval:BIB_6F7D75E34958]
Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Glatard A., Dobrinas M., Gholamrezaee M., Lubomirov R., Cornuz J., Csajka C., Eap C.B., 2017/10. Experimental and clinical psychopharmacology, 25 (5) pp. 353-362. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C398035F5631]
 
Simultaneous determination of selective serotonin reuptake inhibitors and their main metabolites in human breast milk by liquid chromatography-electrospray mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2017/07/01. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1057 pp. 101-109. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_EA86621FAFDC]
 
Prevalence of polypharmacy in the Swiss HIV Cohort Study (SHCS). Le futur c’est maintenant !
Courlet P., Cavassini M., Choong E., Csajka C., Marzolini C., Decosterd L., and the Swiss HIV Cohort Study, 2017/05/03. dans SSMIG SSPTC Spring Meeting, Lausanne EPFL.
[serval:BIB_DFA2081D36EE]
 
Optimiser ses prescriptions : quelle démarche et quel outil ?
Lang P.O., Farhat A., Csajka C., 2017/04/01. Revue de Geriatrie, 42 (4) pp. 207-218. Peer-reviewed.
[serval:BIB_A3E1CDE63ACA]
 
Pharmacometrics-based decision tools facilitate mHealth implementation.
Nekka F., Csajka C., Wilbaux M., Sanduja S., Li J., Pfister M., 2017/04. Expert review of clinical pharmacology, 10 (1) pp. 39-46. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E074D46DFCAE]
 
Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
Aouri M., Barcelo C., Guidi M., Rotger M., Cavassini M., Hizrel C., Buclin T., Decosterd L.A., Csajka C., Swiss HIV Cohort Study, 2017/04. Antimicrobial agents and chemotherapy, 61 (1) p. 10. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_551E69A36AD5]
2016
Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C., Crettol S., Guidi M., Eap C.B., 2016/12. Clinical pharmacokinetics, 55 (12) pp. 1521-1533. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_038FD2A79BD0]
 
Stereoselective determination of citalopram and desmethylcitalopram in human plasma and breast milk by liquid chromatography tandem mass spectrometry.
Weisskopf E., Panchaud A., Nguyen K.A., Grosjean D., Hascoët J.M., Csajka C., Eap C.B., Ansermot N., collaborators of the SSRI-Breast Milk study, 2016/11/30. Journal of pharmaceutical and biomedical analysis, 131 pp. 233-245. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B83BFE02B0D1]
 
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Fuchs A., Rotzinger A., Cavassini M., Bugnon O., Buclin T., Schneider M.P., Csajka C., 2016/08. Therapeutic drug monitoring, 38 (4) pp. 506-515. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C5EDAE96F2A]
 
Population pharmacokinetic analysis of elvitegravir and cobicistat in HIV-1-infected individuals.
Barceló C., Gaspar F., Aouri M., Panchaud A., Rotger M., Guidi M., Cavassini M., Buclin T., Decosterd L.A., Csajka C. et al., 2016/07. The Journal of antimicrobial chemotherapy, 71 (7) pp. 1933-1942. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_001364580150]
 
Outbreak in meldonium positive laboratory tests: are we missing something?
Panchaud A., Csajka C., 2016/04. British journal of sports medicine, 50 (22) pp. 1422-1423. Peer-reviewed.
[DOI][Pmid][serval:BIB_34C01DC804AD]
 
Bon usage des antidépresseurs ISRS durant la grossesse--le défi de l'évaluation de la balance bénéfice-risque [SSRI antidepressant use during pregnancy and the assessment of the risk-benefit ratio].
Weisskopf E., Fumeaux C.J., Bickle Graz M., Harari M.M., Epiney M., Tolsa C.B., Rouiller S., Tolsa J.F., Eap C.B., Vial Y. et al., 2016. Revue Médicale Suisse, 12 (510) pp. 561-566. Peer-reviewed.
[Pmid][serval:BIB_C18A424B9682]
 
Cas clinique n°5 - fibrillation auriculaire.
Guignard B., Beney Johnny, Panchaud Alice, Csajka Chantal, Meyer Philippe, 2016. pharmaJournal 07 pp. 5-9.
[serval:BIB_7A85BB8F0F8F]
 
Pharmacometric Approaches to Personalize Use of Primarily Renally Eliminated Antibiotics in Preterm and Term Neonates.
Wilbaux M., Fuchs A., Samardzic J., Rodieux F., Csajka C., Allegaert K., van den Anker J.N., Pfister M., 2016. Journal of Clinical Pharmacology, 56 (8) pp. 909-935. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_000D0A8CC4BF]
 
Safety of drugs during pregnancy and breastfeeding in cystic fibrosis patients.
Panchaud A., Di Paolo E.R., Koutsokera A., Winterfeld U., Weisskopf E., Baud D., Sauty A., Csajka C., 2016. Respiration; international review of thoracic diseases, 91 (4) pp. 333-348. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C8F67FDB86FD]
Utility of an Algorithm to Increase the Accuracy of Medication History in an Obstetrical Setting.
Corbel A., Baud D., Chaouch A., Beney J., Csajka C., Panchaud A., 2016. Plos One, 11 (3) pp. e0151205. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A5136B4D227F]
2015
 
Suivi thérapeutique pharmacologique des inhibiteurs de protéines kinases
Buclin Thierry, Csajka Chantal, Guiducci Carlotta, Decosterd Laurent A, 2015/09. Innovations & Thérapeutiques en Oncologie, 1 (1) pp. 12-23.
[URN][DOI][serval:BIB_36B4E1B0267A]
 
Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd L.A., Widmer N., Zaman K., Cardoso E., Buclin T., Csajka C., 2015/09. Biomarkers In Medicine, 9 (9) pp. 887-893. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2E88575DAD1C]
 
Vitamin D time profile based on the contribution of non-genetic and genetic factors in HIV-infected individuals of European ancestry.
Guidi M., Foletti G., McLaren P., Cavassini M., Rauch A., Tarr P.E., Lamy O., Panchaud A., Telenti A., Csajka C. et al., 2015/07. Antiviral Therapy, 20 (3) pp. 261-269. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60B0877DA09D]
 
Cas clinique n°4 - prescription inappropriée chez le patient âgé: entre trop et trop peu de médicaments.
Csajka Chantal, Panchaud Alice, Guignard Bertrand, Beney Johnny, Spinewine Anne, 2015. pharmaJournal 7 pp. 5-7.
[serval:BIB_D551A62AEEBB]
Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.
Vandenberghe F., Guidi M., Choong E., von Gunten A., Conus P., Csajka C., Eap C.B., 2015. Clinical Pharmacokinetics, 54 (12) pp. 1259-1272. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_594496D78157]
 
Improved investigations in drug safety by more in-depth individual pharmacokinetics using high-resolution mass spectrometry.
Rochat B., Dahmane E., Zaman K., Csajka C., 2015. Therapeutic Drug Monitoring, 37 (2) pp. 141-146.
[DOI][WoS][Pmid][serval:BIB_A36DFF174E15]
 
Médicaments, grossesse et lactation.
Delaloye J.F., Panchaud A., Weisskopf E., Winterfeld U., Rothuizen L., Vial Y., Csajka C., Buclin T., Hohlfeld P., 2015/01., 4e éd. 252 p, Médecine et Hygiène.
[serval:BIB_267D2934EC39]
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. pp. Abstr. 3505 dans 24th Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[serval:BIB_08604FD033C0]
 
Population pharmacokinetic study to evaluate dosing strategies of imipenem in neonates and infants
Fuchs A., Giannoni E., Guidi M., Decosterd L.A., Marchetti O., Pfister M., Widmer N., Buclin T., Csajka C., 2015. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_D01690AA9CCD]
 
Risk-benefit balance assessment of SSRI antidepressant use during pregnancy and lactation based on best available evidence.
Weisskopf E., Fischer C.J., Bickle Graz M., Morisod Harari M., Tolsa J.F., Claris O., Vial Y., Eap C.B., Csajka C., Panchaud A., 2015. Expert Opinion On Drug Safety, 14 (3) pp. 413-427. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A6E08AD4EF04]
2014
 
Cas clinique n° 3 : médicaments et rein
Beney J., Panchaud A., Guignard B., Csajka C., 2014/10. PharmaJournal 21 pp. 5-7.
[URN][serval:BIB_4F2A78DC1AF4]
 
Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania.
Mosha D., Guidi M., Mwingira F., Abdulla S., Mercier T., Decosterd L.A., Csajka C., Genton B., 2014/08. Antimicrobial Agents and Chemotherapy, 58 (8) pp. 4583-4592. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2037BBD1EF7C]
 
Cas clinique n°2: épilepsie et grossesse.
Panchaud A., Guignard B., Beney J., Baud D., Csajka C., Ferreira E., 2014/06. pharmaJournal, 12 (6) pp. 5-7.
[serval:BIB_68F07874517B]
 
Cas clinique n°1 : Insuffisance cardiaque
Guignard B, Beney J, Panchaud A, Csajka C, De Denus S, 2014/03. PharmaJournal, 7 (3) pp. 5-8.
[URN][serval:BIB_82673EAA3BE1]
 
Caractérisation du profil pharmacocinétique de la vancomycine chez des patients hospitalisés en médecine générale et chirurgie
Ribeiro J., Cerruti J., Widmer N., Livio F., Buclin T., Csajka C., Guidi M., 2014. dans 2e Congrès Suisse des Pharmaciens.
[serval:BIB_53A95AA2370D]
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L., Baerlocher G.M., Duchosal M.A. et al., 2014. Cancer Chemotherapy and Pharmacology, 74 (6) pp. 1307-1319. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8EFC5835C440]
Dosing regimen of gentamicin in neonates: evaluation of current guidelines based on a large population pharmacokinetic analysis
Fuchs A., Guidi M., Giannoni E., Werner D., Widmer N., Buclin T., Csajka C., 2014. dans ESCIM 2014, European and Swiss Congress of Internal Medicin.
[URN][serval:BIB_1EA441B5D179]
 
EzeCHiel: a story of individualized medicine validation - case of gentamicin dosing regimen optimisation in newborns
Fuchs A., Thoma Y., Sutter Y., Stadelmann J., Csajka C., Guidi M., Buclin T., Widmer N., 2014. dans Nano-Tera Annual Plenary Meeting 2014: Virtual Edition.
[serval:BIB_0B32327B859F]
 
High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate.
Mercier T., Tissot F., Gardiol C., Corti N., Wehrli S., Guidi M., Csajka C., Buclin T., Couet W., Marchetti O. et al., 2014. Journal of Chromatography. A, 1369 pp. 52-63. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0D0099C7E204]
 
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Gotta V., Bouchet S., Widmer N., Schuld P., Decosterd L.A., Buclin T., Mahon F.X., Csajka C., Molimard M., 2014. Leukemia Research, 38 (7) pp. 764-772. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0F6749D7DFF3]
 
Médicaments et grossesse : modifications pharmacocinétiques et place du suivi thérapeutique pharmacologique [Pharmacokinetic Alterations in Pregnancy and Use of Therapeutic Drug Monitoring].
Panchaud A., Weisskopf E., Winterfeld U., Baud D., Guidi M., Eap C.B., Csajka C., Widmer N., 2014. Therapie, 69 (3) pp. 223-234. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_18592A49D874]
 
Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Stancu I., Alnawaqil A.M., Bula C. et al., 2014. British Journal of Clinical Pharmacology, 78 (1) pp. 135-144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D0309E8CA034]
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine M., Lubomirov R., Fayet-Mello A., Aouri M., Rotger M., Buclin T., Widmer N., Gatri M., Ledergerber B., Rentsch K. et al., 2014. Journal of Antimicrobial Chemotherapy, 69 (9) pp. 2489-2498. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1E8FAB4C9089]
 
Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates.
Fuchs A., Guidi M., Giannoni E., Werner D., Buclin T., Widmer N., Csajka C., 2014. British Journal of Clinical Pharmacology, 78 (5) pp. 1090-1101. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_44A869ECA1E5]
Quantitative monitoring of tamoxifen in human plasma extended to 40 metabolites using liquid-chromatography high-resolution mass spectrometry: new investigation capabilities for clinical pharmacology.
Dahmane E., Boccard J., Csajka C., Rudaz S., Décosterd L., Genin E., Duretz B., Bromirski M., Zaman K., Testa B. et al., 2014. Analytical and Bioanalytical Chemistry, 406 (11) pp. 2627-2640. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8148F1A0D48C]
 
Risk perception by healthcare professionals related to drug use during pregnancy: a Swiss survey.
Csajka C., Jaquet A., Winterfeld U., Meyer Y., Einarson A., Panchaud A., 2014. Swiss Medical Weekly, 144 pp. w13936.
[URN][DOI][WoS][Pmid][serval:BIB_AF074CA6B747]
Tobramycin exposure from active calcium sulfate bone graft substitute.
Livio F., Wahl P., Csajka C., Gautier E., Buclin T., 2014. Bmc Pharmacology and Toxicology, 15 (1) p. 12. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_A0951C3E3C64]
2013
 
Population pharmacokinetic study of memantine: effects of clinical and genetic factors.
Noetzli M., Guidi M., Ebbing K., Eyer S., Wilhelm L., Michon A., Thomazic V., Alnawaqil A.M., Maurer S., Zumbach S. et al., 2013/03. Clinical pharmacokinetics, 52 (3) pp. 211-223. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6598521C6000]
 
Antidépresseurs, grossesse et allaitement : une étude multicentrique
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J-F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
[serval:BIB_73EE20F9060C]
 
Benchmarking therapeutic drug monitoring software: A review of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2013. Clinical Pharmacokinetics, 52 (1) pp. 9-22. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05B9B2586135]
 
Certificat de formation continue en Pharmacie clinique: une nouvelle opportunité de formation.
Panchaud A., Csajka C., 2013. PharmaJournal, 12 (6) pp. 17-18.
[serval:BIB_A9655AD8E1DC]
 
Clinical pharmacokinetics of imatinib and its therapeutic relevance
Widmer N., Gotta V., Haouala A., Blanc J., von Mehren M., Duchosal M., Leyvraz S., Csajka C., Decosterd L.A., Buclin T., 2013. pp. 15-43 dans Akhtari M., Elhemaidi I. (eds.) Imatinib: Chemical structure, pharmacology and adverse effects chap. 2, Nova Science Publishers.
[serval:BIB_4D7D4CB0B535]
 
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: Results from the randomized controlled I-COME Trial
Gotta V., Widmer N., Decosterd L.A., Chalandon Y., Heim D., Benz R., Gregor M., Leoncini-Franscini L., Baerlocher G., Duchosal M. et al., 2013. pp. e6 dans 11th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT), Clinical Therapeutics. Peer-reviewed.
[DOI][serval:BIB_950BDE93EF84]
 
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M., Crettol S., Oneda B., Lahyani R., Rotger M., Choong E., Lubomirov R., Csajka C., Eap C.B., 2013. Pharmacogenetics and Genomics, 23 (2) pp. 84-93. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_B0FCBF667C36]
 
Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania.
Staehli Hodel E.M., Csajka C., Ariey F., Guidi M., Kabanywanyi A.M., Duong S., Decosterd L.A., Olliaro P., Beck H.P., Genton B., 2013. Antimicrobial Agents and Chemotherapy, 57 (2) pp. 950-958.
[DOI][WoS][Pmid][serval:BIB_0195967C8F4F]
 
Etude multicentrique: antidépresseurs, grossesse et allaitement.
Weisskopf E., Lepigeon K., Fischer C., Morisod M., Bickle M., Eap C.B., Tolsa J.F., Vial Y., Csajka C., Panchaud A., 2013. Forum Gynécologie Suisse, 13 (2) pp. 4-6.
[serval:BIB_05F36D52BCB4]
 
EzeCHiel validation: Comparison of gentamicin drug concentration predictions to a reference method (NONMEM)
Fuchs A., Thoma Y., Csajka C., Buclin T., Widmer N., 2013. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_73165EEF79CB]
Intraocular penetration of penciclovir after oral administration of famciclovir: a population pharmacokinetic model.
Schenkel F., Csajka C., Baglivo E., Kondo-Oestreicher M., Dayer P., Gex-Fabry M., Daali Y., 2013. Journal of Antimicrobial Chemotherapy, 68 (7) pp. 1635-1641. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F38035F9E09]
 
Medikamente, Schwangerschaft und Stillzeit: nicht alle Informationsquellen sind verlässlich
Panchaud A., Berger J., Csajka C., Bugnon O., 2013. PharmaJournal, 151 (1) pp. 16-17.
[serval:BIB_14CEBB66AEE6]
 
Multiplex liquid chromatography-tandem mass spectrometry assay for simultaneous therapeutic drug monitoring of ribavirin, boceprevir, and telaprevir.
Aouri M., Moradpour D., Cavassini M., Mercier T., Buclin T., Csajka C., Telenti A., Rauch A., Decosterd L.A., 2013. Antimicrobial Agents and Chemotherapy, 57 (7) pp. 3147-3158. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8E97B578C370]
 
Médicaments tocolytiques: utilisation en cas de menace d'accouchement prématuré.
Weisskopf E., Lepigeon K., Baud D., Csajka C., Panchaud A., 2013. PharmaJournal, 19 (9) pp. 5-7.
[serval:BIB_6DCBA3059E7C]
 
Médicaments, grossesse et allaitement: toutes les sources d'information ne sont pas fiables!
Panchaud A., Berger J., Csajka C., Bugnon O., 2013. PharmaJournal, 151 (1) pp. 15-16.
[serval:BIB_C0B2106033EA]
 
Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Lubomirov R., Arab-Alameddine M., Rotger M., Fayet-Mello A., Martinez R., Guidi M., di Iulio J., Cavassini M., Günthard H.F., Furrer H. et al., 2013. Pharmacogenetics and Genomics, 23 (1) pp. 9-18. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CDA03D8C1D2B]
Population pharmacokinetic study of gentamicin: A retrospective analysis in a large cohort of neonate patients
Fuchs A., Guidi M., Giannoni E., Buclin T., Widmer N., Csajka C., 2013. pp. Abstr. 2906 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_39F2DCB21916]
Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients.
Staehli Hodel E.M., Guidi M., Zanolari B., Mercier T., Duong S., Kabanywanyi A.M., Ariey F., Buclin T., Beck H.P., Decosterd L.A. et al., 2013. Malaria Journal, 12 p. 235. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35BEA32B625E]
 
Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours.
Haouala A., Widmer N., Guidi M., Montemurro M., Leyvraz S., Buclin T., Eap C.B., Decosterd L.A., Csajka C., 2013. British Journal of Clinical Pharmacology, 75 (4) pp. 1007-1018. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CF51D91AAB14]
 
Relationship of CYP2D6, CYP3A, POR, and ABCB1 Genotypes With Galantamine Plasma Concentrations.
Noetzli M., Guidi M., Ebbing K., Eyer S., Zumbach S., Giannakopoulos P., von Gunten A., Csajka C., Eap C.B., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 270-275. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A5DFF6BBD3DF]
Simulation-based systematic review of imatinib population pharmacokinetics and PK-PD relationships in chronic myeloid leukemia (CML) patients
Gotta V., Buclin T., Widmer N., Csajka C., 2013. pp. Abstr. 2904 dans 22nd Population Approach Group in Europe (PAGE) Meeting, PAGE. Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_12575934C0A0]
 
Systematic review of population pharmacokinetic analyses of imatinib and relationships with treatment outcomes
Gotta V., Buclin T., Csajka C., Widmer N., 2013. Therapeutic Drug Monitoring, 35 (2) pp. 150-167. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_95B21E312150]
2012
 
Antimicrobial Agents
Csajka C., Marchetti O., Manuel O., Decosterd L., Telenti A., 2012. pp. 379-402 dans Anzenbacher P., Zanger U.M. (eds.) Metabolism of Drugs and Other Xenobiotics chap. 14, Wiley-VCH Verlag.
[DOI][serval:BIB_12273AD3B89C]
 
Bedeutet eine radiologische Untersuchung immer eine Gefahr für das ungeborene Kind?
Panchaud A., Verdun F.R., Csajka C., 2012. PharmaJournal, 150 (17) pp. 8-11.
[serval:BIB_57D324A36CF8]
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. 113S-114S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
[serval:BIB_B20EB1D14F5C]
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. pp. Abstr. 2351 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_B2BF81EEDE5B]
 
Benchmarking therapeutic drug monitoring software: A systematic evaluation of available computer tools
Fuchs A., Csajka C., Thoma Y., Buclin T., Widmer N., 2012. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_3D5C70A1DA87]
Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A., Csajka C., Buclin T., Bolay S., Bille J., Calandra T., Marchetti O., 2012. Clinical Infectious Diseases, 55 (3) pp. 381-390.
[URN][DOI][WoS][Pmid][serval:BIB_0A1C9377388D]
 
Cytogenetic response to imatinib in chronic myeloid leukaemia patients: concentration dependency and associated influences under field-conditions
Gotta V., Bouchet S., Widmer N., Csajka C., Buclin T., Mahon F.-X., Molimard M., 2012. pp. 107S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
[serval:BIB_6C22E889082B]
Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.
Glass T.R., Rotger M., Telenti A., Decosterd L., Csajka C., Bucher H.C., Günthard H.F., Rickenbach M., Nicca D., Hirschel B. et al., 2012/01. Plos One, 7 (1) pp. e29186. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5217BD6F9449]
 
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Guidi M., Arab-Alameddine M., Rotger M., Aouri M., Telenti A., Decosterd L.A., Buclin T., Csajka C., Swiss HIV Cohort Study, 2012. Chimia, 66 (5) pp. 291-295. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4CE4C9D2166]
 
Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial
Dahmane E., Zaman K., Galmiche Rindisbacher M., Berthod G., Perey L., Bodmer A., Leyvraz S., Eap C., Decosterd L., Buclin T. et al., 2012. pp. 108S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
[serval:BIB_4BDA40F2AC01]
 
Pharmacie clinique en Suisse romande
Guignard B, Csajka Chantal, Beney J, Bugnon Olivier, Bonnabry Pascal, 2012. pp. 1277-1290 dans Calop J, Limat S, Fernandez C, Aulagner G (eds.) Pharmacie clinique et thérapeutique chap. 65, Elsevier Masson.
[serval:BIB_5F0A644D8CEE]
 
Pharmacokinetic (PK)-based dosage individualization of imatinib: evaluation of efficiency and clinical usefulness
Gotta V., Widmer N., Decosterd L.A., Montemurro M., Leyvraz S., Chalandon Y., Heim D., Gregor M., Benz R., Leoncini-Franscini L. et al., 2012. dans 3rd Symposium of the Swiss Clinical Trial Organisation (SCTO), Personalised Medicine in Clinical Research.
[serval:BIB_10F3BBD6809D]
 
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.
Siccardi M., Almond L., Schipani A., Csajka C., Marzolini C., Wyen C., Brockmeyer N.H., Boffito M., Owen A., Back D., 2012. Clinical Pharmacology and Therapeutics, 92 (4) pp. 494-502.
[DOI][WoS][Pmid][serval:BIB_974D19D0A162]
 
Population pharmacokinetic analysis and pharmacogenetics of raltegravir in HIV-positive and healthy individuals.
Arab-Alameddine M., Fayet-Mello A., Lubomirov R., Neely M., di Iulio J., Owen A., Boffito M., Cavassini M., Günthard H.F., Rentsch K. et al., 2012. Antimicrobial Agents and Chemotherapy, 56 (6) pp. 2959-2966.
[DOI][WoS][Pmid][serval:BIB_6052FCB27C8D]
 
Population pharmacokinetics in chronic myeloid leukaemia patients: observations under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.-X., Molimard M., Buclin T., Csajka C., 2012. pp. 111S-112S dans 80. Jahresversammlung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum. Peer-reviewed.
[serval:BIB_E1C1BA8A0484]
Pragmatic approach for interpreting antiretroviral drug concentrations based on a systematic review of population pharmacokinetic studies
Arab-Alameddine M., Buclin T., Guidi M., Widmer N., Decosterd L.A., Csajka C., 2012. pp. Abstr. 2441 dans 21st Population Approach Group in Europe (PAGE) meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_3D75DE43C185]
 
Pregnancy outcome following exposure to topical retinoids: a multicenter prospective study.
Panchaud A., Csajka C., Merlob P., Schaefer C., Berlin M., De Santis M., Vial T., Ieri A., Malm H., Eleftheriou G. et al., 2012. Journal of Clinical Pharmacology, 52 (12) pp. 1844-1851. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A2D63B38436E]
 
Prevalence, incidence and indications of hypno-sedative treatments in hospitalized patients aged 75 and older
Von Rohr T.R., Rochat S., Monod S., Buela C., Buclin T., Renard D., Csajka C., 2012. p. 228 dans 40th International Symposium on Clinical Pharmacy (ESCP), Clinical Pharmacy: Connecting Care and Outcomes, International Journal of Clinical Pharmacy.
[WoS][serval:BIB_B98C3D34DCC1]
Probability of achieving optimal molecular response to imatinib in chronic myeloid leukemia (CML) patients: Pharmacokinetic/Pharmacodynamic (PK/PD) relationships observed under field-conditions
Gotta V., Bouchet S., Widmer N., Mahon F.X., Molimard M., Buclin T., Csajka C., 2012. pp. Abstr. 2504 dans 21st Population Approach Group in Europe (PAGE) Meeting, Abstracts of the Annual Meeting of the Population Approach Group in Europe. Peer-reviewed.
[URN][serval:BIB_1B447D1B4DAA]
 
Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2012. Clinical Pharmacokinetics, 51 (3) pp. 187-201. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2ED734507B5B]
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective estrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd L.A., Dahmane E., Neeman M., Buclin T., Csajka C., Haouala A., Widmer N., 2012. pp. 197-250 dans Xu Q.A, Madden T.L. (eds.) LC-MS in drug bioanalysis chap. 9, Springer.
[DOI][serval:BIB_D2C7505A3942]
 
Therapeutic drug monitoring of targeted anticancer therapy. Tyrosine kinase inhibitors and selective oestrogen receptor modulators: A clinical pharmacology laboratory perspective
Decosterd LA Dahmane E Neeman M Buclin T Csajka C Haouala A Widmer N, 2012. pp. 197-250 dans LC-MS in Drug Bioanalysis, Springer.
[DOI][serval:BIB_66D3AE3FFDC2]
 
Un examen radiologique est-il toujours à risque pour l'enfant à naître?
Panchaud A., Verdun F. R., Csajka C., 2012. PharmaJournal, 150 (17) pp. 5-8.
[serval:BIB_41F7C08AD1D4]
 
Vancomycin exposure from active calcium sulfate bone filler
Livio F., Guidi M., Wahl P., Gautier E., Prod'Hom G., Buclin T., Csajka T., 2012. pp. 112S dans 80. Jahrestagung der Schweizerischen Gesellschaft für Allgemeine Innere Medizin, Swiss Medical Forum = Forum Médical Suisse.
[serval:BIB_CDC4660C6308]
2011
 
Evaluation of risk perception related to drug use during pregnancy: a swiss survey
Jaquet A., Winterfeld U, Meyer Y., Buclin T., Csajka C., Panchaud A., 2011/02. p. 260 dans Reproductive Toxicology. Peer-reviewed.
[serval:BIB_5671B2BB58B2]
 
Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics.
Arab-Alameddine M., Décosterd L.A., Buclin T., Telenti A., Csajka C., 2011. Expert Opinion On Drug Metabolism and Toxicology, 7 (5) pp. 609-622.
[DOI][WoS][Pmid][serval:BIB_844DA409294E]
Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy.
Buclin T., Telenti A., Perera R., Csajka C., Furrer H., Aronson J.K., Glasziou P.P., 2011. Plos One, 6 (4) pp. e18578.
[URN][DOI][WoS][Pmid][serval:BIB_721ABA6D07F9]
 
Evaluation of risk perception related to drug use during pregnancy: a Swiss survey
Jaquet A., Winterfeld U., Meyer Y., Buclin T., Csajka C., Panchaud A., 2011. pp. 422-423 dans 39th ESCP European Symposium on Clinical Pharmacy and 13th SFPC Congress: Clinical Pharmacy at the Front Line of Innovations, International Journal of Clinical Pharmacy. Peer-reviewed.
[WoS][serval:BIB_9D071EE1F834]
 
Improvement of therapeutic drug monitoring of imatinib by Bayesian prediction of trough levels. Personalized drug dosage
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. p. 478 dans 12th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
[DOI][WoS][serval:BIB_CEAB03974A49]
 
Personalized drug dosage: Monitoring of imatinib concentration with a Bayesian interpretation tool
Gotta V., Widmer N., Montemurro M., Leyvraz S., Haouala A., Decosterd L.A., Csajka C., Buclin T., 2011. dans Nano-Tera Annual Plenary Meeting.
[serval:BIB_D2ECCF2765CA]
 
Prediction of Infant Drug Exposure Through Breastfeeding: Population PK Modeling and Simulation of Fluoxetine Exposure.
Panchaud A., Garcia-Bournissen F., Csajka C., Kristensen J.H., Taddio A., Ilett K.F., Begg E.J., Ito S., 2011. Clinical Pharmacology and Therapeutics, 89 (6) pp. 830-836. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A212696EF074]
2010
 
ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Lubomirov R., di Iulio J., Fayet A., Colombo S., Martinez R., Marzolini C., Furrer H., Vernazza P., Calmy A., Cavassini M. et al., 2010. Pharmacogenetics and Genomics, 20 (4) pp. 217-230.
[DOI][WoS][Pmid][serval:BIB_F0BE883DE124]
 
An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E., Mercier T., Zanolari B., Cruchon S., Guignard N., Buclin T., Leyvraz S., Zaman K., Csajka C., Decosterd L.A., 2010. Journal of Chromatography. B, Analytical Technologies In the Biomedical and Life Sciences, 878 (32) pp. 3402-3414.
[DOI][WoS][Pmid][serval:BIB_70F932215581]
 
Evaluation of the impact of a therapeutic drug monitoring program in a Swiss University Hospital
Fernandez S., Widmer N., Buclin T., Biollaz J., Csajka C., 2010. pp. 283-284 dans ESCP-GSASA, 38th Symposium on Clinical Pharmacy, 30 years of clinical pharmacy : a bright future ahead, Pharmacy World and Science. Peer-reviewed.
[WoS][serval:BIB_16C92C4C7410]
 
Feasibility of Therapeutic Drug Monitoring (TDM) for Imatinib: Preliminary considerations on the dosage adjustment approach for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 90S dans 78. Jahresversammlung der Schweizerischen Gesellschaft für Innere Medizin, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_FCE60B11AFF2]
Imatinib plasma levels: correlation with clinical benefit in GIST patients.
Widmer N., Decosterd L.A., Csajka C., Montemurro M., Haouala A., Leyvraz S., Buclin T., 2010. British Journal of Cancer, 102 (7) pp. 1198-1199. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EF7EF608D142]
 
Population PK-guided simulation study in children exposed to drugs in human milk
Ito S., Garcia-Bournissen F., Panchaud A., Csajka C., Kristensen J., Taddio A., Ilett K., Begg E., Tomlinson G., 2010. p. 40 dans 16th World Congress of Basic and Clinical Pharmacology, Basic and Clinical Pharmacology and Toxicology. Peer-reviewed.
[serval:BIB_625295E90C95]
Prospective assessment of CYP2D6 by genotyping, phenotyping and measurement of tamoxifen, PD 05-09 4-hydroxy-tamoxifen and endoxifen in breast cancer patients treated with tamoxifen.
Zaman K., Dahmane E., Perey L., Buclin T., Berthod G., Bodmer A., Galmiche M., Leyvraz S., Eap C., Csajka C. et al., 2010. dans 33rd Annual San Antonio Breast Cancer Symposium.
[URN][serval:BIB_34EABEDF4890]
Suivi thérapeutique de l'imatinib
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. Forum Medical Suisse, 10 (23) pp. 403-406. Peer-reviewed.
[URN][serval:BIB_FE549E7D44DF]
 
Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study
Gotta V., Widmer N., Decosterd L.A., Csajka C., Duchosal M.A., Chalandon Y., Heim D., Gregor M., Buclin T., 2010. pp. 28S dans Réunion annuelle Société Suisse de Médecine Intensive, Société Suisse d'Infectiologie, Société Suisse d'Hygiène Hospitalière, Société Suisse de Pharmacologie et Toxicologie Cliniques, Communauté Suisse d'intérêts pour soins intensifs, Invité: Société Suisse de Transplantation, Swiss Medical Forum = Forum Médical Suisse. Peer-reviewed.
[serval:BIB_84C101628359]
2009
Tamoxifen metabolism and the impact of Tamoxifen dose on the level of the active metabolites in endocrine sensitive breast cancer patients
Dahmane Elyes, Csajka Chantal, Decosterd Laurent, Mercier Thomas, Zanolari Boris, Eap Chin, Buclin Thierry, Galmiche Marie, Zaman Khalil, 2009/09. dans ''Frontiers in drug discovery and development'' : 24ème séminaire, 3ème cycle, en sciences pharmaceutiques.
[URN][serval:BIB_646DE6013BB6]
 
Exposition du nourrisson aux médicaments à travers le lait maternel : évaluation du degré d'exposition
Panchaud Alice, Csajka Chantal, 2009. Pharmajournal, 147 (9) p. 15.
[serval:BIB_22B2B640C8D3]
 
Formation et recherche en pharmacie hospitalière et communautaire – état des lieux et perspectives en Suisse romande
Pannatier André, Bugnon Olivier, Csajka Chantal, Bonnabry Pascal, 2009. Pharmactuel, 42 (Suppl. 1) pp. 53-61. Peer-reviewed.
[serval:BIB_AE234F1ABC0F]
 
In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
di Iulio J., Fayet A., Arab-Alameddine M., Rotger M., Lubomirov R., Cavassini M., Furrer H., Günthard H.F., Colombo S., Csajka C. et al., 2009. Pharmacogenetics and Genomics, 19 (4) pp. 300-309. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_69748BF486BC]
 
Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.
Arab-Alameddine M., Di Iulio J., Buclin T., Rotger M., Lubomirov R., Cavassini M., Fayet A., Décosterd L.A., Eap C.B., Biollaz J. et al., 2009. Clinical Pharmacology and Therapeutics, 85 (5) pp. 485-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09C3908EC60D]
 
Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir.
Perrottet N., Csajka C., Pascual M., Manuel O., Lamoth F., Meylan P., Aubert J.D., Venetz J.P., Soccal P., Decosterd L.A. et al., 2009. Antimicrobial agents and chemotherapy, 53 (7) pp. 3017-23.
[DOI][WoS][Pmid][serval:BIB_6BCA0E0A0A40]
 
Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine
Garcia-Bournissen F., Panchaud A., Csajka C., Kristensen J.H.., Taddio A, Ilett K.F., Begg E.J., Ito S., 2009. pp. S1 dans 110th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Clinical Pharmacology and Therapeutics. Peer-reviewed.
[WoS][serval:BIB_6443F343035E]
 
Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies.
Lamoth F., Buclin T., Csajka C., Pascual A., Calandra T., Marchetti O., 2009. Antimicrobial Agents and Chemotherapy, 53 (2) pp. 785-787. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3C81678B0325]
2008
 
Efavirenz Dose Adjustment in HIV Patients with Impaired CYP2B6 Function
Csajka C., Cavassini M., Rotger M., Decosterd L. A., Furrer H., Calmy A., Fayet A., Arab-Alameddine M., Widmer N., di Iulio J. et al., 2008. Pharmacotherapy, 28 (9) pp. 215e-216e. Peer-reviewed.
[serval:BIB_B959BE3BFC81]
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
Widmer N., Decosterd L. A., Leyvraz S., Duchosal M. A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2008. British Journal of Cancer, 98 (10) pp. 1633-1640. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5285F3FECE13]
 
Suivi thérapeutique des médicaments (I). Les principes [Principles of therapeutic drug monitoring]
Widmer N., Csajka C., Werner D., Grouzmann E., Decosterd L.A., Eap C.B., Biollaz J., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1644-1668. Peer-reviewed.
[Pmid][serval:BIB_56FB6F49D00F]
 
Suivi thérapeutique des médicaments (II). La pratique clinique [Therapeutic drug monitoring: clinical practice].
Widmer N., Werner D., Grouzmann E., Eap C.B., Marchetti O., Fayet A., Csajka C., Decosterd L.A., Buclin T., 2008. Revue Médicale Suisse, 4 (165) pp. 1649-1660. Peer-reviewed.
[Pmid][serval:BIB_53F56A1C36B3]
2007
 
ADME pathway approach for pharmacogenetic studies of anti-HIV therapy
Lubomirov R., Csajka C., Telenti A., 2007/06. Pharmacogenomics, 8 (6) pp. 623-633.
[DOI][WoS][Pmid][serval:BIB_69D5CFDAB718]
 
Clinical consequences of imatinib plasma concentrations variability in hemato-oncologic patients
Widmer N., Leyvraz S., Duchosal M.A., Rosselet A., Csajka C., Henry H., Debiec-Rychter M., Eap C.B., Biollaz J., Buclin T. et al., 2007. p. 481 dans 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), Therapeutic Drug Monitoring. Peer-reviewed.
[WoS][serval:BIB_6B840EC11A9C]
 
Relations entre les taux plasmatiques d'imatinib et ses effets cliniques
Widmer N., Decosterd L.A., Leyvraz S., Duchosal M.A., Rosselet A., Debiec-Rychter M., Csajka C., Biollaz J., Buclin T., 2007. dans 14es Journées Franco-Suisses de Pharmacie Hospitalière.
[serval:BIB_3A8230D7BEEB]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University